TNF and interstitial lung disease: It should also be noted that compared with patients without an ILD history, patients with a history of ILD were significantly more likely to receive rituximab (19.8 % versus 8.5 %; P < 0.0001) and significantly less likely to receive anti-TNF therapy (46.5 % versus 59.8 %; P < 0.0001).